MaxCyte

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

MLYS

MOMO

MXCT

XPEV

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

AAPL

NFLX

ORCL

PLTR

QCOM

SMCI

SOUN


Stocks rallied sharply this week, with the S&amp;P 500 index hitting a new all-time high. One reason for the bullish sentiment was clarity about the Trump administration&#39;s initial tariff proposals, which are not as

MarketBeat Week in Review – 01/20 - 01/24

MaxCyte Inc

Press Releases

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

Management

MaxCyte Announces Retirement of Board Member Art Mandell

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Health Care

Contracts

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

Earnings

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

AbCellera Biologics

Akoya Biosciences

Atlantic International Corp. - Common Stock

Atlantic International

Bionano Genomics

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals

Codexis

Champions Oncology

Cytek Biosciences

CryoPort

Fortrea Holdings

Harvard Bioscience

Standard BioTools

Lifecore Biomedical

Mesa Laboratories

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

Nautilus Biotechnology, Inc. - Common Stock

Nautilus Biotechnology

Inotiv

OmniAb

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences

Personalis

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Rapid Micro Biosystems, Inc. - Class A Common Stock

Rapid Micro Biosystems

Seer

Alpha Teknova

Stifel

Stephens & Co.

BTIG

Craig-Hallum

Comments

MaxCyte

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell